Taiho Oncology

Taiho Oncology is a commercial-stage oncology company with a core focus on developing and marketing innovative small molecule cancer therapies. The company's lead commercial asset is LONSURF (trifluridine/tipiracil), an oral combination therapy approved for metastatic colorectal and gastric cancer. While the company has an active pipeline, as indicated by recent data presentations at major conferences, its public web presence shows significant technical issues, limiting detailed external analysis of its full pipeline, leadership, and partnerships. The company appears to be in a phase of leadership transition, having recently appointed a new President & CEO.

Platform focused on applying novel delivery and formulation technologies to improve the bioavailability, efficacy, and/or convenience of cornerstone chemotherapies (e.g., using enzyme inhibitors like tipiracil and cedazuridine to enable oral dosing).

In mCRC/mGC, LONSURF competes with other later-line therapies like regorafenib and TAS-102 (the same drug, marketed by Taiho in other regions). In the oral hypomethylating agent space, it would compete against existing IV formulations and, if approved, other oral candidates in development. The broader competitive landscape is intense, with numerous companies developing targeted therapies and immunotherapies across the same tumor types.